Pharmacogenomics and aging: why the same drug works differently after 50

The same dose of the same medication can be therapeutic in one person, ineffective in another, and toxic in a third. This is not a manufacturing defect — it is pharmacogenomics: the science of how your genes determine drug response.

The problem compounds with age. After 50, liver mass decreases by up to 40%, hepatic blood flow drops by 20–50%, and CYP450 enzyme activity — responsible for metabolizing over 80% of commercially available drugs — declines by approximately 30% after age 70. Layer genetic variation on top of age-related decline, and you have a formula for adverse drug reactions that send over 6 million Americans to emergency rooms each year.

Up to 23% of the population carries genetic variants in CYP2C9, CYP2C19, or CYP2D6 that significantly alter drug metabolism. Most have never been tested.

What you’ll learn:

• How aging changes drug metabolism at the molecular level
• The key CYP450 enzymes and their genetic variants
• Why polypharmacy becomes dangerous with age
• How pharmacogenomic testing can protect your longevity

---

What is pharmacogenomics?

Pharmacogenomics is the study of how genetic variations affect individual responses to medications — including how fast you metabolize a drug, how effectively it works, and how likely you are to experience side effects.

Quick definition: Pharmacogenomics explains why the same drug at the same dose can be a cure for one person and a toxin for another — based on variations in the genes that encode drug-metabolizing enzymes.

The CYP450 system

The cytochrome P450 (CYP450) system is a family of enzymes in the liver that metabolizes over 80% of prescribed medications. The key drug-metabolizing CYP450 enzymes are:

Enzyme	Drugs metabolized	Population with variants
CYP2D6	Codeine, tamoxifen, metoprolol, antidepressants	7–10% poor metabolizers
CYP2C19	Clopidogrel, omeprazole, antidepressants	2–15% poor metabolizers
CYP2C9	Warfarin, NSAIDs, sulfonylureas	1–3% poor metabolizers
CYP3A4/5	Statins, calcium channel blockers, immunosuppressants	High variability
CYP1A2	Caffeine, theophylline, clozapine	~50% slow metabolizers

Metabolizer phenotypes

Based on your genetic variants, you fall into one of four categories for each enzyme:

Phenotype	Enzyme activity	Drug effect	Risk
Ultra-rapid	Very high	Drug metabolized too fast — may be ineffective	Treatment failure
Normal (extensive)	Normal	Standard drug response	Baseline
Intermediate	Reduced	Drug metabolized slower — may accumulate	Side effects
Poor	Very low/absent	Drug accumulates significantly	Toxicity

---

How aging changes drug metabolism

Phase I metabolism decline

Phase I reactions (oxidation, reduction, hydrolysis) — primarily performed by CYP450 enzymes — show the most significant age-related decline:

• Liver mass: decreases 20–40% between ages 40 and 90
• Hepatic blood flow: decreases 20–50% — fewer drug molecules reach the liver per minute
• CYP450 activity: declines approximately 30% after age 70
• First-pass metabolism: reduced, meaning more drug reaches systemic circulation unchanged

Phase II metabolism

Phase II reactions (conjugation — glucuronidation, sulfation, acetylation) are relatively preserved with aging. This means drugs primarily metabolized by Phase II pathways may be safer choices for older adults.

The pharmacogenomics-aging interaction

The critical insight: genetic variants that reduce CYP450 activity by 30–50% interact multiplicatively with age-related enzyme decline of 30%. Understanding the full scope of your genetic vulnerabilities — including both drug metabolism genes and disease risk variants — is where polygenic risk scores become a powerful complement to pharmacogenomic testing. A 70-year-old CYP2D6 poor metabolizer may have less than 20% of the enzyme activity of a 30-year-old normal metabolizer. The same drug dose produces dramatically different blood levels.

Polypharmacy amplifies the risk

The average adult over 65 takes 5+ medications. Each drug that inhibits or competes for the same CYP450 enzyme reduces the available capacity for metabolizing other drugs. Combine genetic variants + aging + polypharmacy, and the risk of adverse drug reactions rises exponentially.

---

Key drugs affected by pharmacogenomics in aging

Cardiovascular medications

Drug	Enzyme	Aging concern
Warfarin	CYP2C9	Poor metabolizers need 40–50% lower doses; narrow therapeutic window
Clopidogrel	CYP2C19	Poor metabolizers cannot activate the prodrug — no antiplatelet effect
Statins	CYP3A4	Reduced metabolism increases myopathy risk
Beta-blockers	CYP2D6	Poor metabolizers risk excessive heart rate reduction

Neuropsychiatric medications

Drug	Enzyme	Aging concern
SSRIs	CYP2D6/2C19	Poor metabolizers accumulate drug → increased side effects
Benzodiazepines	CYP3A4	Reduced metabolism + brain sensitivity → falls, confusion
Opioids (codeine)	CYP2D6	Ultra-rapid: toxicity; Poor: no pain relief
Antipsychotics	CYP2D6	Prolonged sedation, movement disorders

Pain medications

Codeine requires CYP2D6 to convert to morphine (the active form). CYP2D6 ultra-rapid metabolizers produce excessive morphine — potentially fatal. Poor metabolizers get no pain relief. This interaction is particularly dangerous in older adults whose renal clearance is also reduced.

---

5 strategies for safer aging with medications

1. Get pharmacogenomic testing

Why it works: A single test reveals your metabolizer status for all major CYP450 enzymes — information that remains valid for life. The FDA has approved pharmacogenomic labeling for over 300 drugs.

How to do it:

• Clinical pharmacogenomic panels are available through healthcare providers
• Direct-to-consumer tests (23andMe, GeneSight) provide partial data
• Share results with your prescribing physician and pharmacist
• Results should be added to your medical record for all future prescriptions

Expected results: personalized dosing, reduced adverse drug reactions, improved treatment effectiveness.

2. Review all medications with a pharmacist annually

Why it works: As your body ages, the same medications you have tolerated for years may begin accumulating or interacting differently. An annual medication review identifies drugs that should be dose-adjusted, switched, or discontinued.

How to do it:

• Schedule a comprehensive medication review with a clinical pharmacist
• Bring all medications, supplements, and over-the-counter drugs
• Ask about drug-drug interactions specific to your CYP450 profile
• Request deprescribing analysis — are you taking anything unnecessary?

Expected results: reduced polypharmacy, fewer side effects, potential improvement in cognitive function and energy.

3. Start low, go slow with new medications

Why it works: The geriatric pharmacology principle of “start low, go slow” accounts for both age-related metabolic decline and potential genetic variations. Starting at 50% of the standard adult dose and titrating slowly reduces the risk of adverse reactions.

How to do it:

• Discuss lower starting doses with your physician for any new medication
• Monitor for side effects carefully during the first 2–4 weeks
• Track relevant biomarkers: resting heart rate, blood pressure, sleep quality
• Report any changes in mood, cognition, balance, or energy

Expected results: safer medication initiation; reduced adverse reaction risk.

4. Monitor drug effects with wearable data

Why it works: Many medication side effects manifest as changes in objective health metrics before subjective awareness: elevated resting heart rate (beta-blocker wearing off), disrupted sleep architecture (SSRI effects), or reduced HRV (anticholinergic burden).

How to do it:

• Track resting heart rate and HRV trends before and after starting new medications
• Monitor sleep quality changes — many drugs disrupt sleep architecture
• Watch for declining exercise tolerance — may signal drug-induced fatigue

Expected results: earlier detection of drug side effects; data-driven conversations with your physician.

5. Optimize liver and kidney health

Why it works: Drug metabolism depends on liver function; drug clearance depends on kidney function. Both decline with age, but the rate of decline is modifiable through lifestyle.

How to do it:

• Maintain healthy liver markers: GGT, AST/ALT
• Monitor kidney function: creatinine, urea/BUN
• Limit alcohol — the most common hepatotoxin
• Stay hydrated — dehydration reduces renal clearance
• Exercise supports hepatic blood flow and liver regeneration

Expected results: preserved drug metabolism capacity; extended drug safety window.

---

How to track and measure medication impact

Key metrics to monitor

Metric	What it reveals	How to track
Resting heart rate	Cardiovascular drug effects	Apple Watch / SuperAge
HRV	Autonomic drug effects	SuperAge daily
Sleep architecture	Drug impact on sleep	Sleep tracking
Blood pressure	Antihypertensive effectiveness	Home monitor
GGT, ALT, creatinine	Liver/kidney drug clearance	Blood tests

---

How SuperAge helps you monitor medication effects

Medications affect your biology 24/7 — but your doctor only sees you occasionally. SuperAge provides continuous monitoring of the metrics most affected by drug-body interactions.

Heart rate and HRV monitoring

SuperAge tracks your resting heart rate and HRV continuously. Changes in these metrics after starting or adjusting medications provide early signals of drug effects — positive or negative — before your next doctor visit.

Sleep quality tracking

Many medications disrupt deep sleep — beta-blockers, SSRIs, and antihistamines are common culprits. SuperAge’s sleep tracking reveals these effects objectively.

Biological age as a medication outcome measure

SuperAge’s biological age integrates all the metrics medications affect. Epigenetic clocks offer an even deeper read — several medications (including metformin and certain supplements) are being tested for their ability to slow epigenetic aging, and pharmacogenomic status may predict who responds best. If a new medication improves your blood pressure but disrupts sleep and reduces HRV, the net effect on biological age may be negative — providing a holistic view of drug impact.

---

Frequently asked questions

Should everyone get pharmacogenomic testing?

Testing is most valuable for people over 50 taking multiple medications, those who have experienced adverse drug reactions, and those starting medications with narrow therapeutic windows (warfarin, clopidogrel, opioids). The FDA recommends testing before prescribing over 300 drugs. The test is done once and valid for life.

Can I still take medications if I am a poor metabolizer?

Absolutely — the goal is dose adjustment, not avoidance. Poor metabolizers typically need lower doses. In some cases (codeine + CYP2D6 poor metabolizer), an alternative medication is prescribed instead. Pharmacogenomics enables safer prescribing, not medication avoidance.

Does aging always reduce drug metabolism?

Phase I metabolism (CYP450-dependent) generally declines with age. Phase II metabolism (conjugation reactions) is relatively preserved. The decline is also influenced by liver health, nutrition, exercise, and concurrent medications. Healthy aging can significantly slow the decline in drug metabolism.

---

Key takeaways

• Drug metabolism declines ~30% after 70: CYP450 activity, liver mass, and hepatic blood flow all decrease
• 23% of people carry significant CYP450 variants: genotype + aging = compounded risk
• Polypharmacy multiplies the danger: drug-drug-gene interactions are exponentially complex
• Pharmacogenomic testing is a one-time investment: results are valid for life and inform all future prescriptions
• Wearable monitoring detects drug effects early: heart rate, HRV, and sleep changes signal medication impact before symptoms

---

Know your enzymes, protect your longevity

The medications that are meant to extend your life may be silently undermining it — if your dose does not match your genotype and your age. Pharmacogenomic testing and continuous health monitoring together create the safest possible framework for aging with medications.

Ready to track how your body responds to your medications? Download SuperAge and start monitoring the heart rate, HRV, sleep, and biological age markers that reveal whether your treatments are helping — or hurting — your longevity.

---

References

1. Sotaniemi EA et al. — “Age and cytochrome P450-linked drug metabolism in humans” — Hepatology (1997)
2. Mangoni AA and Jackson SH — “Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications” — British Journal of Clinical Pharmacology (2004)
3. Shah RR and Smith RL — “Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes” — Drug Metabolism and Disposition (2015)
4. Crews KR et al. — “Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy” — Clinical Pharmacology & Therapeutics (2014)
5. Klomp SD et al. — “Pharmacogenetics of cytochrome P450 (CYP) in the elderly” — Ageing Research Reviews (2020)
6. Pirmohamed M — “Pharmacogenomics: current status and future perspectives” — Nature Reviews Genetics (2023)

---

Last updated: 2026-03-23. This article is regularly reviewed to ensure accuracy.